$DRMA
Dermata Therapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000165495423014016 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.085M $910.0K $892.8K
YoY Change 31.89% 1.93% -2.16%
% of Gross Profit
Research & Development $1.135M $903.0K $1.553M
YoY Change 27.65% -41.87% 94.22%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.220M $1.812M $1.553M
YoY Change 29.69% 16.65% 94.22%
Operating Profit -$1.812M -$2.446M
YoY Change -25.92% 42.86%
Interest Expense $85.86K $90.00K $21.49K
YoY Change 103.99% 318.8% 3201.08%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.134M -$1.720M -$2.425M
YoY Change 27.81% -29.06% 41.55%
Income Tax
% Of Pretax Income
Net Earnings -$2.134M -$1.719M -$2.425M
YoY Change 27.81% -29.09% 41.55%
Net Earnings / Revenue
Basic Earnings Per Share -$0.54 -$3.16
Diluted Earnings Per Share -$0.45 -$0.54 -$197.5K
COMMON SHARES
Basic Shares Outstanding 3.189M shares 3.189M shares 10.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.438M $6.630M $8.067M
YoY Change 19.18% -17.81% -35.99%
Cash & Equivalents $7.438M $6.631M $8.067M
Short-Term Investments
Other Short-Term Assets $532.1K $690.0K $895.2K
YoY Change -22.94% -22.92% -17.3%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.979M $7.320M $8.975M
YoY Change 14.89% -18.44% -34.42%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.00 $3.383K -$1.00
YoY Change -300.0% -338400.0%
TOTAL ASSETS
Total Short-Term Assets $7.979M $7.320M $8.975M
Total Long-Term Assets $4.00 $3.383K -$1.00
Total Assets $7.979M $7.323M $8.975M
YoY Change 14.89% -18.4% -34.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $866.0K $474.5K $483.7K
YoY Change 74.36% -1.92% -37.17%
Accrued Expenses $757.6K $440.0K $1.021M
YoY Change 77.87% -56.89% 139.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.624M $920.0K $1.504M
YoY Change 75.98% -38.84% 25.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.624M $920.0K $1.504M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.624M $916.8K $1.504M
YoY Change 75.98% -39.05% 25.86%
SHAREHOLDERS EQUITY
Retained Earnings -$53.39M -$51.25M -$43.92M
YoY Change 17.1% 16.69% 31.39%
Common Stock $393.00 $319.00 $1.210K
YoY Change -68.1% -73.64% 45.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.355M $6.407M $7.471M
YoY Change
Total Liabilities & Shareholders Equity $7.979M $7.323M $8.975M
YoY Change 14.89% -18.4% -34.42%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$2.134M -$1.719M -$2.425M
YoY Change 27.81% -29.09% 41.55%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.149M -$1.770M -$2.561M
YoY Change -37.06% -30.89% 15.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.956M -40.00K 200.0
YoY Change -20100.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.149M -1.770M -2.561M
Cash From Investing Activities
Cash From Financing Activities 1.956M -40.00K 200.0
Net Change In Cash 806.8K -1.810M -2.561M
YoY Change -144.2% -29.33% -121.03%
FREE CASH FLOW
Cash From Operating Activities -$1.149M -$1.770M -$2.561M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 drma Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
767275 shares
drma Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
2301360 shares
drma Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
663892 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001853816
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3189034 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
770115 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40739
dei Entity Registrant Name
EntityRegistrantName
DERMATA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3218736
dei Entity Address Address Line1
EntityAddressAddressLine1
3525 Del Mar Heights Rd.
dei Entity Address Address Line2
EntityAddressAddressLine2
322
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
800-2543
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
DRMA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3189034 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6631483 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6241294 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
691900 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
703194 usd
CY2023Q3 us-gaap Assets
Assets
7323383 usd
CY2022Q4 us-gaap Assets
Assets
6944488 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
474458 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
496702 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
442359 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
425932 usd
CY2023Q3 us-gaap Liabilities
Liabilities
916817 usd
CY2022Q4 us-gaap Liabilities
Liabilities
922634 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3189034 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
770115 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
319 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
77 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57660152 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51614965 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51253905 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45593188 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6406566 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6021854 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7323383 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6944488 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
902977 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1553295 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2934541 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4761686 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
909001 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
892777 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2887533 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3201111 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1811978 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2446072 usd
us-gaap Operating Expenses
OperatingExpenses
5822074 usd
us-gaap Operating Expenses
OperatingExpenses
7962797 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1811978 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2446072 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5822074 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7962797 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
92767 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
21486 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
161357 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
21486 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1719211 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2424586 usd
us-gaap Net Income Loss
NetIncomeLoss
-5660717 usd
us-gaap Net Income Loss
NetIncomeLoss
-7941311 usd
CY2023Q3 drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-0.54
CY2022Q3 drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-3.16
drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-2.46
drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-11.96
CY2023Q3 drma Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
3189034 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6021854 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131260 usd
CY2023Q1 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
4174985 usd
CY2023Q1 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
153 usd
CY2023Q1 drma Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
-40 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240142 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8088070 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131177 usd
CY2023Q2 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
1512102 usd
CY2023Q2 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
34 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701364 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8030019 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131177 usd
CY2023Q3 drma Issuance Costs
IssuanceCosts
-35419 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1719211 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6406566 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10107104 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
531566 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2786151 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7852519 usd
CY2022Q2 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
4276365 usd
CY2022Q2 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
87 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
55625 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
205947 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2730573 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
9659970 usd
CY2022Q3 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
200 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
55625 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
179358 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2424586 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7470567 usd
us-gaap Profit Loss
ProfitLoss
-5660717 usd
us-gaap Profit Loss
ProfitLoss
-7941311 usd
us-gaap Share Based Compensation
ShareBasedCompensation
393614 usd
us-gaap Share Based Compensation
ShareBasedCompensation
709435 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11294 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
82933 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-22244 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-31504 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16427 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
337677 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
399091 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
932675 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5261626 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7008636 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5651668 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4276365 usd
drma Proceeds From Pre Funded Warrants Exercises
ProceedsFromPreFundedWarrantsExercises
187 usd
drma Proceeds From Pre Funded Warrants Exercises
ProceedsFromPreFundedWarrantsExercises
287 usd
drma Payment For Fractional Shares In Reverse Stock
PaymentForFractionalSharesInReverseStock
40 usd
drma Payment For Fractional Shares In Reverse Stock
PaymentForFractionalSharesInReverseStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5651815 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4276652 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
390189 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2731984 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6241294 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10798806 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6631483 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8066822 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
950 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 usd
CY2021Q3 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
24106 shares
CY2021Q3 drma Class Of Warrant Or Right Exercise Price Of Warrants Or Right
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight
112.00
CY2023Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
6600000 usd
CY2023Q3 drma Accumulated Deficit
AccumulatedDeficit
-51300000 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-5300000 usd
CY2022 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-8800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2424586 usd
us-gaap Net Income Loss
NetIncomeLoss
-5660717 usd
us-gaap Net Income Loss
NetIncomeLoss
-7941311 usd
CY2023Q3 drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
3189034 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1719211 usd
CY2022Q3 drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
767275 shares
drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
2301360 shares
drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
663892 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.96
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4745629 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
503133 shares
CY2023Q2 drma Proceeds Cash From Pipe
ProceedsCashFromPipe
1500000 usd
CY2023Q2 drma Underwriters Discounts And Offering Expenses In Pipe
UnderwritersDiscountsAndOfferingExpensesInPipe
300000 usd
CY2023Q1 drma Increasing Shares Authorized For Issuance
IncreasingSharesAuthorizedForIssuance
1533123 shares
drma Warrant Reduced Description
WarrantReducedDescription
from $21.20 to $2.82 per share upon closing of the March 2023 Offering
drma Reverse Stock Split
ReverseStockSplit
1-for-16
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2023Q1 drma Common Stock Share Issued
CommonStockShareIssued
85000 shares
drma Warrants Exercised During Period Share
WarrantsExercisedDuringPeriodShare
1533123 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4643555 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
437102 shares

Files In Submission

Name View Source Status
drma-20230930_def.xml Edgar Link unprocessable
0001654954-23-014016-index-headers.html Edgar Link pending
0001654954-23-014016-index.html Edgar Link pending
0001654954-23-014016.txt Edgar Link pending
0001654954-23-014016-xbrl.zip Edgar Link pending
drma-20230930.xsd Edgar Link pending
drma_10q.htm Edgar Link pending
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
drma-20230930_cal.xml Edgar Link unprocessable
drma-20230930_pre.xml Edgar Link unprocessable
drma-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drma_10q_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending